MentionFox
Home › funding signals › iXpressGenes, Inc.
Form D · on the record

iXpressGenes — $2.37M Form D filing, June 2025

iXpressGenes, Inc. filed a Form D with the Securities and Exchange Commission on 2025-06-26.

iXpressGenes, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 26, 2025. The filing reports $2.37M sold. Its industry group is Biotechnology. It names John Schmitt (Executive Officer, Director), Joseph Ng (Executive Officer, Director), Barbara Fisk (Director) (SEC Form D, June 26, 2025).

5 more Biotechnology raises within 90 days of this one ↓

Is this your company?

Key facts

Run the free check on iXpressGenes, Inc. →

Sell to companies like iXpressGenes, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

iXpressGenes, Inc.

New Form D on file · 2025-06-26 · the record

$2.37M
raise on the record
D
filing
13
investors in
ALABAMA
based
Open the record →

What the record says

FilingForm D
Filed2025-06-26
Industry groupBiotechnology
Entity typeCorporation
Incorporated inALABAMA
BasedHUNTSVILLE, ALABAMA
CIK2074283
Accession0002074283-25-000001

Pitching, partnering or investing alongside them? See who really runs and owns iXpressGenes, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind iXpressGenes, Inc., from the filings we hold.

More raises like this

Biotechnology raises filed within 90 days of this one, largest first.

What do you want to do with iXpressGenes, Inc.?

Get the full cited report on iXpressGenes, Inc.

What the filing shows about iXpressGenes, Inc.

  • 13 investors had already put money in when it filed.
  • The filing names 4 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on iXpressGenes, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives iXpressGenes, Inc.'s address as 601 Genome Way Northwest, Huntsville, AL 35806.

What the filing says

  • Offered: $4,184,000. Sold: $2,370,000. Left to sell: $1,814,000. (filing)
  • Investors: 13 had already invested. (filing)
  • Date of first sale: September 16, 2009. (filing)
  • Types of securities: Equity. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on iXpressGenes, Inc. See pricing

Is iXpressGenes, Inc. a real, registered company?

iXpressGenes, Inc. is a registered filer with the SEC (CIK 2074283) and has filed since 2025-06-26. 1 filing is on record, the latest on 2025-06-26.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs iXpressGenes, Inc.?

iXpressGenes, Inc.'s Form D of 2025-06-26 names John Schmitt, Joseph Ng, Barbara Fisk and 1 more as its officers, directors or promoters.

How much has iXpressGenes, Inc. raised?

Its new offerings report $2.37M sold across 1 offering, as its own filings state.

Biotechnology · by week

Trailing twelve months. 769 filings in Biotechnology, totalled by week.

Want the whole picture on iXpressGenes, Inc.?

What the filing shows about iXpressGenes, Inc.

  • 13 investors had already put money in when it filed.
  • The filing names 4 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on iXpressGenes, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on iXpressGenes, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind iXpressGenes, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

RSS

Tools for this story

Each opens in a new tab, filled in for iXpressGenes, Inc.. With no account yet, you sign up free and land on the result.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

iXpressGenes, Inc.: Raised $2.37M, Form D filed 2025-06-26
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/ixpressgenes-inc-form-d-25000001
Last updated 2026-11-01
Primary record: SEC filing 1 · SEC filing 2
iXpressGenes raised $2.37M — SEC Form D filing, June 2025. MentionFox, 2026-11-01. https://mentionfox.com/funding/ixpressgenes-inc-form-d-25000001